{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:10:17Z","timestamp":1783897817580,"version":"3.55.0"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the study was to observe the safety and efficacy of anlotinib (ANL) alone or combined with S-1 in the first-line treatment of advanced hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Fifty-four patients with untreated advanced HCC who could not be resected were randomly divided into the ANL group (n = 27) and ANL+S-1 group (n = 27). The ANL group was given 10 mg ANL orally once a day for 14 consecutive days, stopped for 1 week, and repeated every 21 days. The ANL+S-1 group was given 10 mg ANL once a day orally and 40 mg S-1 twice a day orally for 14 consecutive days, stopped for 1 week, repeated every 21 days. All patients were treated until the disease progressed or toxicity became unacceptable. For patients who could not tolerate adverse reactions, the ANL dose should be reduced to 8 mg per day. CT or MRI was reviewed every 6 weeks to evaluate the efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 44 patients were included in the results analysis, including 22 patients in the ANL group and 22 patients in the ANL+S-1 group. In the ANL group, the objective response rate (ORR) was 4.5% (1\/22), the disease control rate (DCR) was 77.3% (17\/22), the median progression-free survival (PFS) was 4.2 months (95% CI: 3.6\u20136.0) and the median overall survival (mOS) was 7.0 months (95% CI: 6.3\u20139.0). In the ANL+S-1 group, the ORR was 18.2% (4\/22), the DCR was 59.1% (13\/22), the median PFS was 4.0 months (95% CI: 3.6\u20135.4) and the mOS was 6.0 months (95% CI: 5.5\u20137.4). There was no significant difference in ORR (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.345) or DCR (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.195) between the two groups. Adverse reactions were mainly hypertension, anorexia, fatigue, liver transaminase heightened and hand and foot skin reaction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ANL monotherapy was effective in the treatment of advanced HCC, and adverse reactions have been able to tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2023-0036","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T15:09:16Z","timestamp":1690384156000},"page":"405-410","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study"],"prefix":"10.2478","volume":"57","author":[{"given":"Mafei","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology , Affiliated Hospital of Guilin Medical University , Guangxi Guilin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Affiliated Hospital of Guilin Medical University , Guangxi Guilin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Affiliated Hospital of Guilin Medical University , Guangxi Guilin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Affiliated Hospital of Guilin Medical University , Guangxi Guilin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Affiliated Hospital of Guilin Medical University , Guangxi Guilin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"2026071215195903360_j_raon-2023-0036_ref_001","doi-asserted-by":"crossref","unstructured":"Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 4115\u201327. doi: 10.3748\/wjg.v20.i15.4115","DOI":"10.3748\/wjg.v20.i15.4115"},{"key":"2026071215195903360_j_raon-2023-0036_ref_002","doi-asserted-by":"crossref","unstructured":"Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; CD004787. doi: 10.1002\/14651858.CD004787.pub2","DOI":"10.1002\/14651858.CD004787.pub2"},{"key":"2026071215195903360_j_raon-2023-0036_ref_003","doi-asserted-by":"crossref","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378\u201390. doi: 10.1056\/NEJMoa0708857","DOI":"10.1056\/NEJMoa0708857"},{"key":"2026071215195903360_j_raon-2023-0036_ref_004","doi-asserted-by":"crossref","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25\u201334. doi: 10.1016\/s1470-2045(08)70285-7","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"2026071215195903360_j_raon-2023-0036_ref_005","doi-asserted-by":"crossref","unstructured":"Li Q, Su T, Zhang X, Pan Y, Ma S, Zhang L, et al. A real-world study of optimal treatment with anlotinib first-line therapy in advanced hepatocellular carcinoma. Cancer Manag Res 2022; 14: 3037\u201346. doi: 10.2147\/cmar.S379911","DOI":"10.2147\/CMAR.S379911"},{"key":"2026071215195903360_j_raon-2023-0036_ref_006","doi-asserted-by":"crossref","unstructured":"Chen XQ, Zhao YX, Zhang CL, Wang XT, Zhang X, Chen X, et al. Effectiveness and safety of anlotinib with or without PD-1 blockades in the treatment of patients with advanced primary hepatocellular carcinoma: a retrospective, real-world study in china. Drug Des Devel Ther 2022; 16: 1483\u201393. doi: 10.2147\/dddt.S358092","DOI":"10.2147\/DDDT.S358092"},{"key":"2026071215195903360_j_raon-2023-0036_ref_007","doi-asserted-by":"crossref","unstructured":"Murer F, Pozzan C, Peserico G, Farinati F. Capecitabine in advanced hepatocellular carcinoma. Dig Liver Dis 2016; 48: 1260\u20131. doi: 10.1016\/j.dld.2016.06.037","DOI":"10.1016\/j.dld.2016.06.037"},{"key":"2026071215195903360_j_raon-2023-0036_ref_008","doi-asserted-by":"crossref","unstructured":"Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol 2018; 144: 403\u201314. doi: 10.1007\/s00432-017-2556-6","DOI":"10.1007\/s00432-017-2556-6"},{"key":"2026071215195903360_j_raon-2023-0036_ref_009","doi-asserted-by":"crossref","unstructured":"Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep 2017; 7: 42499. doi: 10.1038\/srep42499","DOI":"10.1038\/srep42499"},{"key":"2026071215195903360_j_raon-2023-0036_ref_010","doi-asserted-by":"crossref","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329\u201338. doi: 10.1055\/s-2007-1007122","DOI":"10.1055\/s-2007-1007122"},{"key":"2026071215195903360_j_raon-2023-0036_ref_011","doi-asserted-by":"crossref","unstructured":"Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 2020; 20: 1001\u201314. doi: 10.3892\/ol.2020.11685","DOI":"10.3892\/ol.2020.11685"},{"key":"2026071215195903360_j_raon-2023-0036_ref_012","doi-asserted-by":"crossref","unstructured":"Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res 2019; 38: 71. doi: 10.1186\/s13046-019-1093-3","DOI":"10.1186\/s13046-019-1093-3"},{"key":"2026071215195903360_j_raon-2023-0036_ref_013","doi-asserted-by":"crossref","unstructured":"Tang X, Zheng Y, Jiao D, Chen J, Liu X, Xiong S, et al. Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-MET pathway and activation of ERK1\/2 pathway in H446 cells. Anticancer Agents Med Chem 2021; 21: 747\u201355. doi: 10.2174\/1871520620666200718235748","DOI":"10.2174\/1871520620666200718235748"},{"key":"2026071215195903360_j_raon-2023-0036_ref_014","doi-asserted-by":"crossref","unstructured":"Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018; 19: 1338\u201350. doi: 10.1016\/s1470-2045(18)30495-9","DOI":"10.1016\/S1470-2045(18)30495-9"},{"key":"2026071215195903360_j_raon-2023-0036_ref_015","doi-asserted-by":"crossref","unstructured":"Lan W, Zhao J, Chen W, Shang H, Peng J, Lin J. Anlotinib overcomes multiple drug resistant colorectal cancer cells via inactivating PI3K\/AKT pathway. Anticancer Agents Med Chem 2021; 21: 1987\u201395. doi: 10.2174\/1871520621666210112113852","DOI":"10.2174\/1871520621666210112113852"},{"key":"2026071215195903360_j_raon-2023-0036_ref_016","doi-asserted-by":"crossref","unstructured":"Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med 2018; 7: 4570\u201383. doi: 10.1002\/cam4.1664","DOI":"10.1002\/cam4.1664"},{"key":"2026071215195903360_j_raon-2023-0036_ref_017","doi-asserted-by":"crossref","unstructured":"Zhen L, Jiali C, Yong F, Han X, Hongming P, Weidong H. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study. J Cancer 2018; 9: 2773\u20137. doi: 10.7150\/jca.26376","DOI":"10.7150\/jca.26376"},{"key":"2026071215195903360_j_raon-2023-0036_ref_018","doi-asserted-by":"crossref","unstructured":"Xie XH, Wang F, Lin XQ, Qin YY, Xie ZH, Zhang JX, et al. Anlotinib plus S-1 for patients with EGFR mutation-negative advanced squamous cell lung cancer with PS scores of 2\u20133 after progression of second-line or later-line treatment. Cancer Manag Res 2020; 12: 12709\u201314. doi: 10.2147\/cmar.S278068","DOI":"10.2147\/CMAR.S278068"},{"key":"2026071215195903360_j_raon-2023-0036_ref_019","doi-asserted-by":"crossref","unstructured":"Xiang M, Yang X, Ren S, Du H, Geng L, Yuan L, et al. Anlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: a phase II clinical trial. Oncologist 2021; 26: e2130\u2013e5. doi: 10.1002\/onco.13950","DOI":"10.1002\/onco.13950"},{"key":"2026071215195903360_j_raon-2023-0036_ref_020","doi-asserted-by":"crossref","unstructured":"Yang X, Xiang M, Geng L, Wen Y, Du X. Anlotinib combined with S-1 in the third-line treatment of stage IV non-small cell lung cancer: study protocol for phase II clinical trial. Asian Pac J Cancer Prev 2019; 20: 3849\u201353. doi: 10.31557\/apjcp.2019.20.12.3849","DOI":"10.31557\/APJCP.2019.20.12.3849"},{"key":"2026071215195903360_j_raon-2023-0036_ref_021","doi-asserted-by":"crossref","unstructured":"Song D, Song M, Bae S, Chung W, Jang J, Kim Y, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol 2015; 50: 445\u201354. doi: 10.1007\/s00535-014-0978-3","DOI":"10.1007\/s00535-014-0978-3"},{"key":"2026071215195903360_j_raon-2023-0036_ref_022","doi-asserted-by":"crossref","unstructured":"Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, et al. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun 2019; 39: 36. doi: 10.1186\/s40880-019-0383-7","DOI":"10.1186\/s40880-019-0383-7"},{"key":"2026071215195903360_j_raon-2023-0036_ref_023","doi-asserted-by":"crossref","unstructured":"Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thorac Cancer 2019; 10: 551\u20136. doi: 10.1111\/1759-7714.12977","DOI":"10.1111\/1759-7714.12977"},{"key":"2026071215195903360_j_raon-2023-0036_ref_024","doi-asserted-by":"crossref","unstructured":"Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 2021; 15: 621\u20139. doi: 10.1007\/s12072-021-10171-0","DOI":"10.1007\/s12072-021-10171-0"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2023-0036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:02:57Z","timestamp":1783897377000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2023-0036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7,26]]},"published-print":{"date-parts":[[2023,9,1]]}},"alternative-id":["10.2478\/raon-2023-0036"],"URL":"https:\/\/doi.org\/10.2478\/raon-2023-0036","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}